Wooridul Huebrain Limited completed the acquisition of JS Pharm Co.,Ltd from Jeonghoon Lee, Taehoon Lee, Hong Ji-yong and Hong Ji-wan.
June 10, 2021
Share
Wooridul Huebrain Limited (KOSE:A118000) agreed to acquire JS Pharm Co.,Ltd from Jeonghoon Lee, Taehoon Lee, Hong Ji-yong and Hong Ji-wan for KRW 8 billion on March 11, 2021. Under the terms of the transaction, Wooridul Huebrain Ltd. will acquire 0.051 million shares of JS Pharm Co.,Ltd. After the transaction, Wooridul Huebrain Ltd will hold 100% stake in JS Pharm Co.,Ltd.. Wooridul Huebrain Ltd. will fund the transaction from own funds and long-term borrowing. The financials of JS Pharm Co.,Ltd, for the financial year ending December 31, 2020, are total assets of KRW 4.61 billion, equity of KRW 3.13 billion, revenues of KRW 12.63 billion and net profit of KRW 1.71 million. The Board of Directors passed a resolution for the transaction on March 11, 2021. The transaction is expected to be completed on March 11, 2021.
Wooridul Huebrain Limited (KOSE:A118000) completed the acquisition of JS Pharm Co.,Ltd from Jeonghoon Lee, Taehoon Lee, Hong Ji-yong and Hong Ji-wan on June 11, 2021.
SMeDi Co Ltd, formerly The MediPharm Co Ltd, is a Korea-based company primarily engaged in the pharmaceutical distribution business. The Company operates through five segments. The Pharmaceuticals Business segment is engaged in the distribution of pharmaceuticals including recapsules and tablets. The Medical Business segment is engaged in the distribution of medical devices and medical supplies. The Wireless Device segment is engaged in the manufacture of wearable wireless devices. The Video Content segment is engaged in the production of video products. The Investment segment is engaged in the management consulting and investment businesses.
SMEDI CO., LTD. 
